1 / 42

Human Subject Issues in Research: Informed Consent

Human Subject Issues in Research: Informed Consent. Jill M. Baren, MD. What is Ethics?. The study of standards and conducts and moral judgment The system or code of morals of a particular person, religion, group, or profession. Identifying Ethical Issues.

ngc
Télécharger la présentation

Human Subject Issues in Research: Informed Consent

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Human Subject Issues in Research: Informed Consent Jill M. Baren, MD

  2. What is Ethics? • The study of standards and conducts and moral judgment • The system or code of morals of a particular person, religion, group, or profession

  3. Identifying Ethical Issues • Write down 2 ethical issues, problems or questions that you have encountered since becoming an academic associate • How were they resolved? • Did you feel the resolution was satisfactory?

  4. INFORMED CONSENT • What is it? • Why do we need it? • From whom do we get it? • How do we get it? • How can we be sure we’re doing it right?

  5. What it’s not A legal document A risk management tool for an investigator or an institution A formality What it is A Process Acknowledging respect for persons (Autonomy) Informed Consent

  6. Goal • “The goal of the informed consent process is to provide people with sufficient information so they can make informed choices about whether to begin or continue participation in clinical research.”

  7. The process • “…involves a dynamic and continuing exchange of information between the research team and participant throughout the research experience…”

  8. The document • “…a starting point for the necessary exchange of information between investigator and potential participant.” • “…the foundation not the entirety…”

  9. Why do we need it? • Respect for persons • Respect for autonomy of decision making • True limit on investigative authority • Sense of formality

  10. Historical Perspective • Research ethics policies • From singular events and the reactions to them • Rarely proactive

  11. Nazi war crimes Human radiation experiments, etc. Tuskegee Syphilis study Nuremberg trial (1948) Declaration of Helsinki (1963) National Commission Belmont Report (1977) Sentinel events

  12. Nuremberg, GermanyDecember 9, 1946 to August 20, 1947 • Required voluntary consent prior to participation • Investigator responsibility to obtain consent • Information gained by using human subjects would be unprocurable any other way

  13. Declaration of Helsinki(World Medical Association) • Articulated ethical principles for use by physicians conducting human research • Affirmed the autonomy of the individual • Universally adopted to ensure the rights and welfare of human subjects of research

  14. Tuskegee Syphilis Study

  15. Post- Tuskegee Events • National Research Act 1974 • National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research • Belmont Report • Ethical foundation for US federal regulations on human subjects research

  16. Belmont Report • 3 basic principles that should govern all research involving human subjects • Respect for persons • Beneficence (maximize benefits, minimize risks, avoid harm) • Justice (benefits and burdens equally distributed)

  17. Federal regulations (DHHS) • 1991 Federal Policy for Protection of Human Subjects (The Common Rule) • Adopted by all agencies which conduct, supervise, regulate, fund or sponsor human research • Two major requirements: • Informed Consent • IRB approval

  18. What does someone need to know? • Disclosure (what’s going to happen) • Risks • Benefits • Alternatives • Confidentiality • Compensation

  19. “It’s a very simple procedure. We slice off the top of your head, scoop out your innards with a spoon, and carve out your eyes and mouth.”

  20. Standards for Disclosure • Subjective • “The reasonable volunteer”

  21. Are we doing it right? • Voluntariness: • Freely coming to a decision • Free from coercion or undue influence • Assumes capacity • Capacity • Understand nature and ramifications • Who is not able to do this?

  22. Vulnerable populations • Children ? • Prisoners? • Mentally retarded individuals • Dementia/Coma/Vegetative state • Mental illness • Pregnant women • Emergency patients? (pain, fear, etc.)

  23. Vulnerable Populations: Children • If child can understand (> age 6-8) • We are obligated to obtain assent • Can parents overrule? • In studies with more than minimal risk and not without prospect of direct benefit

  24. Other vulnerable populations • Research on individuals who lack capacity also requires prospect of benefit • Not promulgated in federal regulations • Family member can consent • If consistent with state law

  25. How do we get informed consent? • Will vary according to study design and nature of participation • Verbal vs. Written • Investigator vs. proxy

  26. Are we doing it right? • Behaviors during informed consent (>1000 ED patients taking a survey) • 41% did not read • 57% who read spent < 60 seconds • 22% asked questions • 44% did not accept the form

  27. Informed consent behaviors • No relationship with gender, education, marital status, or self-reported health status • We need to do better to correct these behaviors Baren et al: AEM May 2000

  28. Informed consent gone wrong? • Jesse Gelsinger (gene transplant) • James Quinn (artificial heart) • Johns Hopkins (hexamethonium death)

  29. Gene therapy business: “The tragic case of Jesse Gelsinger” • 18 year old with partial ornithine transcarbamylase deficiency • Usually fatal in infancy • The first person to die from gene therapy

  30. Reactions • FDA suspended all gene therapy trials and other experiments • Hearings on quality of oversight and safety • President Clinton demanded improvements in consent and access to information about gene therapy research

  31. James “Butch" Quinn:Artificial Heart Recipient • 52 year old who received the Abiomed heart • Lived for 10 monthswith the device • Sustained fatal stroke

  32. Reactions • Lawsuit over consent process • Recipient's widow says she and her husband were misinformed and misled on risks, benefits and the potential for pain and suffering • “There was no quality of life. It was too painful. He said he wished he'd never done it."

  33. Was it wrong? • 13-pages detailing "significant risks" • stroke, brain and organ damage, discomfort and pain. • “New and experimental operation” • Complications could occur (previously unknown or unforeseen) • Potential benefits “uncertain and not proven”

  34. Volunteer in Asthma Study Dies After Inhaling Drug • 24 hours after inhaling hexamethonium reported dry cough, shortness of breath, muscular aches and fever • 2 days later admitted with concern for possible reaction • Died one month later

  35. Reactions • Research suspended • Federal government temporarily shut down most research involving human subjects at JHU • Hexamethonium not approved by the FDA and IRB did not provide adequate oversight

  36. Healthy volunteers • Volunteers may not stand to benefit directly, but could ultimately contribute to development of a new therapy that the participant might then use. • Require particularly close monitoring, because they can pose a risk to a volunteer's health or life.

  37. Why do people participate in biomedical research? • Altruism • Free medical care and medications • Trust • Self-interest • Attention • Do we want to constrain people if they are doing things for the wrong reasons?

  38. “A motion has been made and seconded that we stick our heads in the sand.”

  39. Role of the IRB • Protect the institution • Can introduce complexity • Responsibility of PI to terminate if they sense the patient is not really involved in the process • No one knows how risk is really determined

  40. How can we make it better? Start with the document Finish with the process

  41. Discussion • Current studies • Ethical issues • Your opinions?

More Related